Table 3.

Statistical analysis for major response rate by CXCR4, TP53, TERT, and ARID1A mutational status in patients with WM with MYD88^MUT

	Univariate analysis∗		Multivariate analysis†		Multivariate analysis‡
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
CXCR4MUT	0.533 (0.249, 1.142)	.106	0.718 (0.308, 1.677)	.444	-	-
CXCR4FS	0.638 (0.230, 1.768)	.387	-	-	0.737 (0.251, 2.167)	.579
CXCR4NS	0.454 (0.177, 1.167)	.101	-	-	0.701 (0.242, 2.027)	.512
TP53MUT	0.520 (0.239, 1.132)	.100	0.625 (0.276, 1.411)	.258	0.626 (0.277, 1.415)	.260
TERTMUT	0.269 (0.099, 0.729)	.010	0.345 (0.118, 1.014)	.053	0.348 (0.117, 1.038)	.058

Patients with CXCR4^MUT, TP53^MUT, and TERT^MUT trended toward lower VGPR + CR rate, lower MRR, and/or longer median time to response than patients with the respective WT alleles.

Abbreviations are explained in Table 2.

^∗To compare the response rates, univariate logistic regression models were performed, and the odds ratio (95% CI) and the corresponding P values are shown.

^†Odds ratio (95% CI) and P values were estimated using a multivariate logistic regression model with treatment arm and CXCR4 (WT and MUT), TERT (WT and MUT), and TP53 (WT and MUT) mutational status as covariates to account for the correlations among the mutations and the treatment differences between treatment arms. WT was the reference group. The same models were performed to further compare the response rates between CXCR4^WT and CXCR4^NS or CXCR4^FS (CXCR4 [WT, FS, and NS]).

^‡MYD88 status was assessed by polymerase chain reaction–based assay, with a total of 190 patients with MYD88^MUT WM.